Clinical Trials - April 19, 2026
Evaxion’s AI-Immunology platform demonstrates 86% vaccine target precision
Evaxion has announced new data demonstrating that AI-Immunology identifies and selects the most therapeutically relevant vaccine targets.
Clinical Trials - April 15, 2026
Promising results about new Lyme disease vaccine candidate
Pfizer and Valneva's Lyme disease vaccine candidate demonstrated strong efficacy in their Phase 3 VALOR trial.
Clinical Trials - April 13, 2026
Mendus starts clinical program in chronic myeloid leukemia
The company has completed preparations and received all regulatory approvals for the VITAL-CML trial.
Clinical Trials - April 13, 2026
Diamyd Medical discontinues Phase 3 trial and initiates strategic review
Diamyd Medical has announced that it will discontinue the Phase 3 DIAGNODE-3 trial evaluating retogatein (rhGAD65) in Stage 3 type 1 diabetes.
Clinical Trials - April 1, 2026
Cereno Scientific reports 12-month data
The company has announced initial learnings from the 12-month Expanded Access Program (EAP) with its lead drug candidate CS1 in pulmonary arterial hypertension (PAH).
Clinical Trials - March 31, 2026
Affibody reports positive Phase 3 data
The company has announced positive 32-week data from a global Phase 3 study of the next generation IL-17A inhibitor izokibep in hidradenitis suppurativa (HS).
